In tumor cell lysates, PARP activity is inhibited >90% at 100 nM olaparib, and in colony forming assays, an EC50 value of ~250 nM olaparib was observed with a BRCA1-mutant breast cancer line incubated for 7–14 days [128]. This evidence concerns the gene BRCA1 and breast carcinoma.